Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Nat Struct Mol Biol. 2010 Feb;17(2):248-50. doi: 10.1038/nsmb.1723. Epub 2010 Jan 24.
Motavizumab is approximately tenfold more potent than its predecessor, palivizumab (Synagis), the FDA-approved monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection. The structure of motavizumab in complex with a 24-residue peptide corresponding to its epitope on the RSV fusion (F) glycoprotein reveals the structural basis for this greater potency. Modeling suggests that motavizumab recognizes a different quaternary configuration of the F glycoprotein than that observed in a homologous structure.
莫他珠单抗的效力大约比其前体帕利珠单抗（Synagis）高十倍，后者是一种经美国食品药品监督管理局批准的用于预防呼吸道合胞病毒（RSV）感染的单克隆抗体。莫他珠单抗与 RSV 融合（F）糖蛋白上其表位相对应的 24 个残基肽形成复合物的结构揭示了这种更高效力的结构基础。建模表明，莫他珠单抗识别的 F 糖蛋白的四级结构不同于在同源结构中观察到的结构。
